Phase 2 NSCLC Clinical Trials
27 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 27 trials
Recruiting
Phase 1Phase 2
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NSCLC
Regeneron Pharmaceuticals231 enrolled40 locationsNCT04077099
Recruiting
Phase 2
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
NSCLC
Shanghai Chest Hospital124 enrolled1 locationNCT05798845
Recruiting
Phase 1Phase 2
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Lung CancerNSCLCBrain Metastases
Joshua Palmer56 enrolled3 locationsNCT05987644
Recruiting
Phase 1Phase 2
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 2
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
NSCLCBrain MetastasesROS1 Gene Rearrangement
MedSIR20 enrolled16 locationsNCT06315010
Recruiting
Phase 2
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
NSCLC
Jiangsu Cancer Institute & Hospital33 enrolled1 locationNCT07082179
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled1 locationNCT07397338
Recruiting
Phase 2
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
NSCLC
Tianjin Medical University Cancer Institute and Hospital41 enrolled1 locationNCT07330037
Recruiting
Phase 2
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
NSCLC
HC Biopharma Inc.50 enrolled1 locationNCT07169552
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled12 locationsNCT06922591
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled10 locationsNCT05786924
Recruiting
Phase 2
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NSCLC
Eikon Therapeutics70 enrolled39 locationsNCT06246110
Recruiting
Phase 2
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
ChemotherapyNSCLCTislelizumab+1 more
Zibo Municipal Hospital20 enrolled1 locationNCT07198217
Recruiting
Phase 2
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
NSCLCLocally Advanced
Nitin Ohri76 enrolled1 locationNCT06865339
Recruiting
Phase 2
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
NSCLC
Tang-Du Hospital27 enrolled3 locationsNCT06864624
Recruiting
Phase 2
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
ChemotherapyNSCLCTislelizumab+1 more
Zibo Municipal Hospital20 enrolled1 locationNCT07085182
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 1Phase 2
Study of LP-184 in Patients With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorTNBC - Triple-Negative Breast Cancer+4 more
Lantern Pharma Inc.175 enrolled9 locationsNCT05933265
Recruiting
Phase 2
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
NSCLCLow Dose RadiotherapyNeoadjuvant Immunotherapy+1 more
Anhui Provincial Cancer Hospital86 enrolled1 locationNCT06714708